Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 4%

Greenwich LifeSciences, Inc. (NASDAQ:GLSI)’s stock price dropped 4% during trading on Wednesday . The stock traded as low as $12.36 and last traded at $12.62. Approximately 28,642 shares changed hands during mid-day trading, a decline of 37% from the average daily volume of 45,720 shares. The stock had previously closed at $13.14.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of Greenwich LifeSciences in a research report on Wednesday, February 28th.

Greenwich LifeSciences Trading Up 6.3 %

The firm’s 50-day moving average price is $15.54 and its 200 day moving average price is $11.84. The company has a market capitalization of $168.96 million, a price-to-earnings ratio of -18.74 and a beta of 1.38.

Greenwich LifeSciences (NASDAQ:GLSI) last released its quarterly earnings data on Monday, April 15th. The company reported ($0.21) earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that Greenwich LifeSciences, Inc. will post -0.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Snehal Patel acquired 4,100 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was acquired at an average cost of $13.03 per share, for a total transaction of $53,423.00. Following the transaction, the chief executive officer now directly owns 5,340,277 shares in the company, valued at $69,583,809.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders purchased a total of 23,800 shares of company stock worth $327,722 in the last three months. 52.86% of the stock is owned by corporate insiders.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.